Target intelligence / Profile preview

Enhancer of rudimentary homolog (ERH)

Target
ERH
Molecular classification
Other, RNA-binding protein, Pre-mRNA splicing factor
01

Overview

Enhancer of rudimentary homolog (ERH) is a small, highly conserved nuclear protein (about 100–110 amino acids) found in most eukaryotes. It functions as a scaffold in numerous RNA-protein complexes involved in RNA polymerase II transcript processing; its best-characterized roles are as a pre-mRNA splicing factor, especially for genes required for the cell cycle and DNA damage response. ERH is necessary for proper mitosis—it ensures appropriate chromosome alignment by facilitating the splicing and expression of key mitotic regulators like centromere-associated protein E (CENP-E). It is also critical for efficient DNA replication and repair via regulation of ATR mRNA splicing and the broader DNA damage response pathways. Beyond splicing, ERH may participate in transcriptional repression, heterochromatin formation, and RNA biogenesis, including miRNA and piRNA pathways. ERH is overexpressed in several cancers, and its expression is correlated with adverse prognosis and genomic instability. However, no specific therapies targeting ERH are in development, and it is not currently considered a therapeutic target.

Other names
ERHEnhancer of rudimentary homologDROER
02

Biological functions

mRNA splicingCell cycle regulation/mitosisDNA damage responseTranscriptional repressionGenome integrity maintenance
03

Disease associations

CancerOther

Beyond the preview

Go deeper on Enhancer of rudimentary homolog (ERH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enhancer of rudimentary homolog (ERH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call